- ►prsjournal.com [PDF] KC Madhusudhana, SR Hannan, CPR Williams, … - British Medical Journal, 2007 - bjo.bmj.com J Lotery, AJ Luff and RSB Newsom KC Madhusudhana, SR Hannan, CPR Williams, SV
Goverdhan, C Rennie, A ... 118 cases age-related macular degeneration: results
from treatment of choroidal neovascularization in Intravitreal bevacizumab ( ... Cited by 6 - Related articles - All 5 versions
R LAZIC, N Gabric, I Dekaris, B Saric, M … - Collegium antropologicum, 2007 - cat.inist.fr To evaluate the efficacy and safety of intravitreal bevacizumab in treatment of
minimally classic and occult choroidal neovascularization secondary to
age-related macular disease 48 eyes of 48 patients(mean age of 74. 8) ... Cited by 3 - Related articles - BL Direct - All 3 versions
F Giansanti, G Virgili, A Bini, E Rapizzi, G … - European journal of ophtalmology, 2007 - cat.inist.fr PURPOSE. To investigate the 6-month safety and clinical outcomes of intravitreal
injections of bevacizumab administered to treat choroidal neovascularization
secondary to age-related macular degeneration. METHODS. Twenty-seven ... Cited by 18 - Related articles - BL Direct - All 2 versions
L Wu, J Fernando Arevalo, M Maia, MH … - Japanese Journal of Ophthalmology, 2009 - Springer Choroidal neovascularization (CNV) is responsible for 80% to 90% of cases of
severe vision loss due to age-related macular degeneration (AMD). 1–3 Vascular
endothelial growth factor (VEGF) appears to play a major role in the ... Related articles - All 2 versions
KE Schmid-Kubista, I Krebs, B Gruenberger, F … - British Medical Journal, 2009 - bjo.bmj.com Methods: Subjects with fibrovascular pigment epithelial detachment, subfoveal
choroidal neovascularisation extending under the geometric centre of the foveal
avascular zone and/or macular thickness of at least 300 µm in both eyes ... Related articles - All 7 versions
ML Subramanian, S Ness, G Abedi, E Ahmed, M … - American Journal of Ophthalmology, 2009 - Elsevier This is a single-center, randomized clinical trial at the Boston Veterans
Affairs Healthcare System. Patients who met inclusion criteria were randomized
2:1 to bevacizumab or ranibizumab. Each patient contributed 1 eye to the ... Related articles - All 2 versions
KC Madhusudhana, RSB Newsom - Eye, 2009 - nature.com Jump to main content; Jump to navigation; nature.com homepage; Publications AZ index;
Browse by subject. My account; Submit manuscript; Register; Subscribe; RCOphth ... Related articles
ZF Bashshur, A Schakal, RN Hamam, CP El … - Archives of Ophthalmology, 2007 - archopht.highwire.org Methods Patients with predominantly classic CNV were prospectively randomized to
receive standard PDT or intravitreal bevacizumab injections (2.5 mg).
Best-corrected visual acuity (BCVA) measured by Snellen charts, central ... Cited by 19 - Related articles - BL Direct - All 3 versions
CA Cleary, S Jungkim, K Ravikumar, C … - Eye, 2007 - nature.com A total of 112 eyes of 111 patients received injections. Median follow-up was 5
months (range: 1–12 months). Mean log MAR vision pre-injection was 0.84 0.03
(n=112); at 3 months was 0.69 0.05 (P<0.0001, n=84); at 6 months was 0.74 ... Cited by 26 - Related articles - BL Direct - All 3 versions
RV Azad, MA Khan, B Chanana, S Azad - Japanese Journal of Ophthalmology, 2008 - Springer Exudative age-related macular degeneration (AMD) is a major cause of legal
blindness in the elderly worldwide.1,2 Hitherto, the standard treatment options
were laser photo- coagulation and photodynamic therapy, both of which have ... Cited by 8 - Related articles - All 2 versions
